益心舒片联合瑞舒伐他汀治疗稳定型心绞痛合并高脂血症的临床研究  

Clinical Study of Yixinshu Tablets Combined with Rosuvastatin in the Treatment of Stable Angina Pectoris Complicated with Hyperlipidemia

作　　者：王卫星 李乾坤 WANG Weixing;LI Qiankun(Department of Cardiology,Shijingshan Teaching Hospital of Capital Medical University(Beijing Shijingshan Hospital),Beijing 100040,China)

机构地区：[1]首都医科大学石景山教学医院(北京市石景山医院)急救站,北京100040 [2]首都医科大学石景山教学医院(北京市石景山医院)心内科,北京100040

出　　处：《中国医学创新》2025年第11期50-57,共8页Medical Innovation of China

摘　　要：目的:探讨益心舒片联合瑞舒伐他汀治疗稳定型心绞痛(SAP)合并高脂血症的临床效果。方法:选取首都医科大学石景山教学医院(北京市石景山医院)2022年1月—2024年10月收治的SAP合并高脂血症患者153例,按随机数字表法分为联合组、对照1组和对照2组,各51例。联合组给予益心舒片联合瑞舒伐他汀治疗,对照1组用瑞舒伐他汀治疗,对照2组用益心舒片治疗,均治疗8周。比较三组心绞痛症状疗效、降脂疗效、心绞痛发作相关指标、血清学指标、血液流变学指标及安全性。结果:联合组的心绞痛症状、降脂总有效率分别为92.16%、94.12%,均显著高于对照1组的76.47%、80.39%和对照2组的74.51%、76.47%,差异均有统计学意义(P<0.05)。联合组治疗后的心绞痛发作次数少于对照1组和对照2组,持续时间短于对照1组和对照2组,视觉模拟评分法(VAS)评分低于对照1组和对照2组,差异均有统计学意义(P<0.05)。联合组治疗后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、基质金属蛋白酶-9(MMP-9)、可溶性CD40配体(sCD40L)、白细胞介素-6(IL-6)水平和血浆黏度(PV)、纤维蛋白原(FIB)、红细胞聚集指数(EAI)、红细胞变形指数(EDI)均显著低于对照1组和对照2组,高密度脂蛋白胆固醇(HDL-C)水平显著高于对照1组和对照2组,差异均有统计学意义(P<0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:益心舒片联合瑞舒伐他汀治疗SAP合并高脂血症的总体效果确切,能有效改善患者心绞痛发作情况及脂代谢异常,并可进一步改善血液流变性,降低血清炎症因子水平,且治疗安全性较好。Objective:To investigate the clinical effect of Yixinshu Tablets combined with Rosuvastatin in the treatment of stable angina pectoris(SAP)complicated with hyperlipidemia.Method:A total of 153 patients with SAP complicated with hyperlipidemia admitted to Shijingshan Teaching Hospital of Capital Medical University(Beijing Shijingshan Hospital)from January 2022 to October 2024 were selected and divided into the combination group,control group 1 and control group 2 according to random number table,with 51 cases in each group.The combination group was treated with Yixinshu Tablets combined with Rosuvastatin,the control group 1 was treated with Rosuvastatin,and the control group 2 was treated with Yixinshu Tablets,all of which were treated for 8 weeks.The angina pectoris symptoms effect,lipid-lowering effect,angina pectoris attack related indexes serological indexes,hemorheological indexes and safety of the three groups were compared.Result:The total effective rate of angina pectoris symptoms and lipid-lowering in combination group were 92.16%and 94.12%,respectively,which were significantly higher than 76.47%and 80.39%in control group 1 and 74.51%and 76.47%in control group 2,the differences were statistically significant(P<0.05).After treatment,the frequency of angina pectoris in combination group was less than that in control group 1 and control group 2,the duration time was shorter than that in control group 1 and control group 2,and the visual analogue scale(VAS)score was lower than that in control group 1 and control group 2,the differences were statistically significant(P<0.05).Total cholesterol(TC),lowdensity lipoprotein cholesterol(LDL-C),triglycerides(TG),matrix metalloproteinase-9(MMP-9),soluble CD40 ligand(sCD40L),interleukin-6(IL-6)levels and plasma viscosity(PV),fibrinogen(FIB),erythrocyte aggregation index(EAI),erythrocyte deformability index(EDI)in combination group after treatment were significantly lower than those of control group 1 and control group 2,the high density lipoprotein cholesterol(HDL-C)le

关 键 词：益心舒片 瑞舒伐他汀 稳定型心绞痛 高脂血症 血液流变学 炎症反应 

分 类 号：R541.4[医药卫生—心血管疾病]